Tomoyasu Ishikawa

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

Kathleen Aertgeerts, R.J. Skene, Jason K. Yano et al. · Journal of Biological Chemistry · 2011 · 431 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-<i>d</i>]pyrimidine Scaffold

Tomoyasu Ishikawa, Masaki Seto, Hiroshi Banno et al. · Journal of Medicinal Chemistry · 2011 · 216 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells

Akihiro Ohashi, Momoko Ohori, Kenichi Iwai et al. · Nature Communications · 2015 · 200 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Structure-Based Approach for the Discovery of Pyrrolo[3,2-<i>d</i>]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors

Satoshi Sogabe, Youichi Kawakita, S. Igaki et al. · ACS Medicinal Chemistry Letters · 2012 · 167 citations · Full text

Medicine, Oncology, Pharmacology +13

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

Tomoyasu Ishikawa, Nobuyuki Matsunaga, H. TAWADA et al. · Bioorganic & Medicinal Chemistry · 2003 · 137 citations

Pharmacy, Medicinal Chemistry, Pharmacology +10